Can I read EE507 Insulin Degludec/Insulin Aspart Versus Basal+Bolus Insulin Treatment (Insulin Glargine U100 & Insulin Aspart) in T2D in India: A Short-Term Cost-Effectiveness Analysis Based on the Step-By-Step Clinical Trial on EtoBox?

EE507 Insulin Degludec/Insulin Aspart Versus Basal+Bolus Insulin Treatment (Insulin Glargine U100 & Insulin Aspart) in T2D in India: A Short-Term Cost-Effectiveness Analysis Based on the Step-By-Step Clinical Trial by S Das; KD Modi; PV Rao; MK Pathan; M Revanna; J Garcia Uranga is a Economics, Econometrics and Finance article available to read on EtoBox.

What is EE507 Insulin Degludec/Insulin Aspart Versus Basal+Bolus Insulin Treatment (Insulin Glargine U100 & Insulin Aspart) in T2D in India: A Short-Term Cost-Effectiveness Analysis Based on the Step-By-Step Clinical Trial about?

annually (65.1% of total excess cost), being absenteeism the main driver; V630V (21.4%) and 23.3 (19.0-27.5) extra sick-leave days in migraineurs, p,0.001. NHSfunded healthcare PPPY cost represented the 30.5% of total excess cost; V898 (736-1,061), mainly due to higher utilization of medical visits. Conclusions: In Spain, from a nationwide society perspective, migraineurs showed a meaningful per-patient-peryear excess cost compared with non-migraineurs. Given that it is expected to have about 3.5 million migraineurs in Spain, the overall economic impact was estimated to be above 10,502 million Euros in year 2020. As in many other developed countries, most of the excess cost was driven by productivity losses.

Who reads EE507 Insulin Degludec/Insulin Aspart Versus Basal+Bolus Insulin Treatment (Insulin Glargine U100 & Insulin Aspart) in T2D in India: A Short-Term Cost-Effectiveness Analysis Based on the Step-By-Step Clinical Trial?

Author

S Das; KD Modi; PV Rao; MK Pathan; M Revanna; J Garcia Uranga

Publisher

Elsevier BV

Published

2022

Language

EN

Field

Economics, Econometrics and Finance (Social Sciences)